23andme Holding Co's ability to collect accounts receivable sequentially worsen to 53.15, indicating more challenging environment then in the fourth quarter 2025, but still, it is a far cry from any concerns. 23andme Holding Co's Accounts Receivable average collection period in the Jun 30 2025 quarter, has increased to 7 days, from 6 days, in the Mar 31 2025 quarter.

If we take a look into Healthcare sector 27 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 257, from overall ranking in the fourth quarter 2025 at 1499.

What is Receivable Turnover Ratio?
What is 23andme Holding Co Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ME Receivables Turnover Ratio	(Jun 30 2025) I. Quarter	(Mar 31 2025) IV. Quarter	(Dec 31 2024) III. Quarter	(Sep 30 2024) II. Quarter	(Jun 30 2024) I. Quarter
Y / Y Receivable Change	11.56 %	-59.33 %	-44.51 %	-70.29 %	-73.35 %
Y / Y Revenue Change	-37.92 %	-28.87 %	36.17 %	-12.71 %	-34.88 %
Receivable Turnover Ratio (TTM)	53.15	58.29	55.62	33.34	32.93
ME's Total Ranking	# 257	# 1499	# 1254	# 361	# 2349
Accounts Receivable average collection period days	7	6	7	11	11
Seq. Receivable Change	-9.32 %	-86.58 %	2158.52 %	-59.42 %	-66.94 %
Seq. Revenue Change	-46.97 %	-22.68 %	37.83 %	9.85 %	-39.24 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 12
Healthcare Sector	# 28
Overall Market	# 257

Receivable Turnover Ratio Statistics
High	Average	Low
58.29	30.65	13.8
(Mar 31 2025)		(Jun 30 2023)

News about 23andme Holding Co Receivables Turnover Ratios

Emerging Insights 23andMes Therapeutics Breakthroughs in Oncology and the Intersection of Genetics with GLP-1 Medi...

In recent developments within precision medicine, 23andMe Therapeutics has announced significant progress in its clinical research endeavors, particularly regarding cancer treatment and weight management therapies. The company s notable findings stem from the ongoing studies of two investigational drugs: 23ME-00610 and 23ME-01473. These agents are currently under investigation for their potential therapeutic efficacy in oncology, specifically in renal cell carcinoma and immuno-oncology settings. Clinical Trials and Preliminary FindingsThe Phase 2 results for 23ME-00610 indicate promising outcomes in patients with clear-cell renal cell carcinoma (ccRCC). This investigational therapy has demonstrated preliminary evidence of clinical benefit, marked by one confirmed partial response in a cohort of participants. The ongoing research aims to further elucidate the drug s mechanisms and effectiveness, with correlative biomarker data expected to provide additional insight into the subset of patients who may benefit most from this treatment approach.

Unraveling the Genetic Tapestry New Perspectives on Sickle Cell Trait, GLP-1 Medications, and Lung Cancer Genetics fr...

In recent years, collaborative research efforts spearheaded by 23andMe, often in partnership with prestigious institutions such as the National Human Genome Research Institute and Johns Hopkins University, have yielded significant insights into a range of critical health topics including sickle cell trait implications, the effectiveness of new weight loss medications, and genetic factors in lung cancer. These studies not only aim to enhance our understanding of genetic predispositions across diverse populations but also to empower individuals with knowledge that can potentially improve health outcomes. This article delves into the findings and implications of these diverse studies, highlighting their significance in the broader context of personalized medicine.The realm of genetics is rapidly evolving, enabling researchers to uncover vital information about individual susceptibilities to various health conditions and responses to treatments. Recent collaborative studies involving 23andMe have shed light on topics that not only impact certain populations but also have far-reaching implications across demographics. This article reviews some of the most notable findings from three major studies that focus on sickle cell trait and its association with blood clots, the role of genetics in the effectiveness of GLP-1 medications for weight loss, and advances in lung cancer genetics research.

ME Company Profile • Back to ME Efficiency Comparisons • Compare ME Receivables Turnover Ratio to its Competitors

Financial Statements
23andme Holding Co's Accounts Receivable	$ 1 Millions	Visit ME's Balance sheet
23andme Holding Co's Sales TTM	$ 174 Millions	Visit ME's Income Statement
Sources of ME's Revenues		Visit ME's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ME's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ME's Growth Rates	ME's Roa	ME's Inventory Turnover Ratio	ME's Dividend Comparisons
ME's Profitability Ratios	ME's Roi	ME's Asset Turnover Ratio	ME's Dividend Growth
ME's Valuation Ratios	ME's Roe	ME's Financial Strength Ratios	ME's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2025	Receivable at quarter ending Jun 30 2025
Bausch Health Companies Inc	337.03	$ 9,858.000 Millions	$ 29.250 Millions
Iqvia Holdings Inc	322.05	$ 15,700.000 Millions	$ 48.750 Millions
Ginkgo Bioworks Holdings Inc	311.07	$ 230.815 Millions	$ 0.742 Millions
Agenus Inc	242.59	$ 101.706 Millions	$ 0.419 Millions
Stoke Therapeutics Inc	220.94	$ 199.894 Millions	$ 0.905 Millions
Arcus Biosciences Inc	209.60	$ 262.000 Millions	$ 1.250 Millions
Fortress Biotech Inc	190.71	$ 57.784 Millions	$ 0.303 Millions
Protagonist Therapeutics inc	185.28	$ 209.180 Millions	$ 1.129 Millions
Monte Rosa Therapeutics Inc	156.61	$ 177.986 Millions	$ 1.137 Millions
Earth Science Tech Inc	143.46	$ 32.639 Millions	$ 0.228 Millions
Sbc Medical Group Holdings Incorporated	127.71	$ 294.794 Millions	$ 2.308 Millions
Wave Life Sciences Ltd	123.65	$ 93.946 Millions	$ 0.760 Millions
Mersana Therapeutics inc	109.85	$ 34.769 Millions	$ 0.317 Millions
Eyepoint Inc	101.17	$ 51.898 Millions	$ 0.513 Millions
Atara Biotherapeutics Inc	99.79	$ 291.685 Millions	$ 2.923 Millions
Orthofix Medical Inc	98.64	$ 809.046 Millions	$ 8.202 Millions
Pavmed Inc	96.35	$ 1.108 Millions	$ 0.012 Millions
Immutep Limited	88.58	$ 10.331 Millions	$ 0.117 Millions
Zeo Scientifix Inc	88.28	$ 4.789 Millions	$ 0.054 Millions
Humacyte Inc	87.27	$ 19.243 Millions	$ 0.221 Millions
Nakamoto Inc	86.77	$ 2.240 Millions	$ 0.026 Millions
Logicmark Inc	82.43	$ 10.400 Millions	$ 0.126 Millions
Lifevantage Corp	63.75	$ 227.666 Millions	$ 3.571 Millions
Aclaris Therapeutics Inc	60.77	$ 16.788 Millions	$ 0.276 Millions
Airsculpt Technologies Inc	60.06	$ 165.109 Millions	$ 2.749 Millions
Brookdale Senior Living Inc	58.34	$ 3,191.923 Millions	$ 54.712 Millions
Cytomx Therapeutics Inc	54.90	$ 141.100 Millions	$ 2.570 Millions
23andme Holding Co	53.15	$ 174.020 Millions	$ 3.274 Millions
Longduoduo Co Ltd	48.80	$ 4.263 Millions	$ 0.087 Millions
X4 Pharmaceuticals Inc	48.13	$ 32.774 Millions	$ 0.681 Millions

Date modified: 2026-08-29T17:43:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.